Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity
Mahesh R. Nepal(Yeungnam University), Alex Sparreboom(The Ohio State University), Muhammad Erfan Uddin(The Ohio State University), Hanieh Taheri(The Ohio State University), Alice A. Gibson(The Ohio State University), Shuiying Hu(The Ohio State University), Maryam B. Lustberg(Yale Cancer Center), Yang Li(Institute of Vegetables and Flowers), Yan Jin(The Ohio State University), Zahra Talebi(The Ohio State University), Duncan F. DiGiacomo(The Ohio State University)
Cited by 12
Related Papers
Cremophor EL
|European Journal of Cancer|2001|1.6k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
|PubMed|2001|752